Summary
Johnson & Johnson reported strong performance for the second quarter and first six months of 2014, with worldwide sales increasing by 9.1% and 6.3% respectively compared to the prior year periods. This growth was driven by significant operational improvements, particularly in the Pharmaceutical segment, which saw sales jump 21.1% in the quarter and 16.1% year-to-date, boosted by new product launches like OLYSIO®/SOVRIAD® and strong performance from existing blockbusters like ZYTIGA® and XARELTO®. The company also demonstrated improved profitability, with earnings before taxes increasing by 17.4% for the quarter and 22.0% year-to-date. This was supported by disciplined cost management, including reduced selling, marketing, and administrative expenses as a percentage of sales, and a lower effective tax rate benefiting from a tax benefit related to the Conor Medsystems divestiture. Despite challenges in the Medical Devices and Diagnostics segment, which experienced modest growth, the overall financial health of the company appears robust.
Financial Highlights
54 data points| Revenue | $19.50B |
| Cost of Revenue | $6.04B |
| Gross Profit | $13.46B |
| SG&A Expenses | $5.48B |
| Operating Income | $5.88B |
| Interest Expense | $128.00M |
| Net Income | $4.33B |
| EPS (Basic) | $1.53 |
| EPS (Diluted) | $1.51 |
| Shares Outstanding (Basic) | 2.83B |
| Shares Outstanding (Diluted) | 2.87B |
Key Highlights
- 1Worldwide sales increased by 9.1% to $19.5 billion in Q2 2014 and by 6.3% to $37.6 billion for the first six months of 2014, driven by strong operational growth.
- 2The Pharmaceutical segment was a key growth driver, with Q2 sales up 21.1% and year-to-date sales up 16.1%, largely due to new product launches and strong performance of key drugs.
- 3Earnings before taxes showed significant improvement, rising 17.4% in Q2 and 22.0% year-to-date, reflecting robust sales and effective cost management.
- 4Selling, marketing, and administrative expenses decreased as a percentage of sales in both the quarter and year-to-date periods, indicating improved operational efficiency.
- 5The company reported a lower effective income tax rate of 18.1% for the first six months of 2014 compared to 19.0% in the prior year, aided by a significant tax benefit from the Conor Medsystems divestiture.
- 6Johnson & Johnson declared a regular quarterly cash dividend of $0.70 per share and announced a new $5.0 billion share repurchase program, signaling confidence in future cash flows and commitment to shareholder returns.
- 7The divestiture of the Ortho-Clinical Diagnostics business for approximately $4.0 billion was completed subsequent to the quarter, with an expected after-tax gain of $1.0 billion in Q3 2014.